Australia's most trusted
source of pharma news
Monday, 03 August 2026
Posted 3 August 2026 AM
The TGA has approved GSK’s Exdensur, two generics of PBS listed medicines, and a handful of over-the-counter medicines.
Exdensur is indicated as add-on maintenance treatment of severe asthma in patients aged 12 years and older with type 2 inflammation characterised by an eosinophilic phenotype who are inadequately controlled on medium-to-high-dose inhaled corticosteroids plus another asthma controller.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.